Acute Heart Failure (AHF) Therapeutics Market 2021 to 2027 | With Top Comprehensive Analysis by Leading Players: Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Etc…
SEATTLE, April 08, 2021, (PHARMIWEB) — Global Acute Heart Failure (AHF) Therapeutics Market – Insights
Acute heart failure (AHF) is characterized by the inability of heart muscles to pump enough blood through the heart to meet body’s optimal blood and oxygen level. The condition is progressive. It is important to distinguish between acute and chronic heart failure for effective medication. N terminal proB-type natriuretic peptide levels are used to distinguish acute versus chronic left ventricular dysfunction.
The symptoms of heart failure vary from person to person. Fluid accumulation or congestion and poor blood flow to the body lead to symptoms such as shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen. Reduced blood flow to parts of the body may lead to dizziness, rapid heart rate, and fatigue.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1910
Smoking, obesity, consumption of high fat and cholesterol food, and physical inactivity may lead to heart attack and stroke. Moreover, heart failure may also lead to coronary artery disease, myocardial infraction, high blood pressure or hypertension, abnormal heart valves, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe lung disease, obesity, and sleep apnea, among others.
Global Acute Heart Failure (AHF) Therapeutics Market: Drivers
Increasing approval and launch of new drugs is expected to propel growth of the global acute heart failure therapeutics market over the forecast period. For instance, in July 2015, the U.S. Food and Drug Administration (FDA) approval Novartis’ Entresto (sacubitril/valsartan) tablets for the treatment of heart failure with reduced ejection fraction.
Moreover, clinical trials for new drugs are also expected to aid in growth of the market. For instance, in March 2017, CXL-1427, a novel nitroxyl donor (prodrug) developed by Cardioxyl Pharmaceuticals (a part of Bristol-Myers Squibb Company), is in phase 2 clinical development phase. CXL-1427 is indicated for the treatment of acute decompensated heart failure (ADHF).
Global Acute Heart Failure (AHF) Therapeutics Market: Restraints
Evidence-based data on treatment of heart failure in the acute setting is limited and current individual treatment options have variable efficacy. The treatment also requires customized approach. For instance, dyspnea is the most common symptom associated with AHF patients. However, this symptom is non-specific as other medical conditions are commonly associated with dyspnea, including pneumonia, exacerbations of chronic obstructive pulmonary disease, pulmonary embolism, acute coronary syndrome, and asthma. Such scenario is expected to hinder growth of the acute heart failure (AHF) therapeutics market.
Global Acute Heart Failure (AHF) Therapeutics Market: Opportunities
High incidence of obesity is expected to offer lucrative growth opportunities for players in the market. For instance, according to the World Health Organization (WHO), October 2017 data findings, in 2016, over 1.9 billion adults were overweight worldwide, of which over 650 million were obese.
Global Acute Heart Failure (AHF) Therapeutics Market: Regional Analysis
North America is expected to account for the largest market share in the hold dominant position in global acute heart failure (AHF) therapeutics market over the forecast period. This is attributed to increasing incidence of acute heart failure in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), June 2016, around 5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the people who develop heart failure die within five years of diagnosis.
Moreover, high incidence of obesity is also expected to aid in growth of the market in North America. For instance, According to CDC, May 2017 data findings, between 2013 and 2014, 37.9% of adults aged 20 years and over were obese, in the U.S.
Increasing focus of healthcare organizations in creating awareness regarding risks factors of acute heart failure is expected to boost growth of the market in Asia Pacific. For instance, in June 2016, Fortis Hospital, India, launched Fortis Heart Rhythm and Heart failure Centre in Bangalore to increase awareness among people regarding heart failure, stroke, and various other cardiovascular diseases.
Global Acute Heart Failure (AHF) Therapeutics Market: Competitive Landscape
Major players operating in the global acute heart failure (AHF) therapeutics market in this market include, Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc..
Quick Buy – Acute Heart Failure (AHF) Therapeutics Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1910
Global Acute Heart Failure (AHF) Therapeutics Market: Key Developments
Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in October 2015, Cardiorentis AG announced plans to collaborate with Roche to establish therapeutic efficacy and safety of Ularitide: Cardiorentis’ investigational drug for acute heart failure (AHF). Under the terms of collaboration, Cardiorentis will incorporate Roche’s advanced in vitro diagnostic tests into its TRUE-AHF Phase III study to characterize the pharmacological properties of Ularitide, evaluate its benefit-risk profile, and the appropriate clinical application in patients.
Global Acute Heart Failure (AHF) Therapeutics Market Taxonomy
By Disorder Type
- Right-sided Heart Failure
- Left-sided Heart Failure
- Systolic Failure
- Diastolic Failure
- Congestive Heart Failure
By Drug Category
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Captopril (Capoten)
- Enalapril (Vasotec)
- Fosinopril (Monopril)
- Lisinopril (Prinivil, Zestril)
- Perindopril (Aceon)
- Quinapril (Accupril)
- Ramipril (Altace)
- Angiotensin II Receptor Blockers
- Candesartan (Atacand)
- Losartan (Cozaar)
- Valsartan (Diovan)
- Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
- If Channel Blocker
- Ivabradine (Corlanor)
- Beta Blockers
- Bisoprolol (Zebeta)
- Metoprolol Succinate (Toprol XL)
- Carvedilol (Coreg)
- Aldosterone Antagonists
- Spironolactone (Aldactone)
- Eplerenone (Inspra)
- Furosemide (Lasix)
- Bumetanide (Bumex)
- Torsemide (Demadex)
- Chlorothiazide (Diuril)
- Amiloride (Midamor Chlorthalidone (Hygroton)
- Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril)
- Anticoagulants (Blood Thinners)
- Cholesterol Lowering Drugs (Statins)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire